Article
Immunology
Yu-Min Zhong, Kai Yin, Yu Chen, Zhi Xie, Zhi-Yi Lv, Jin-Ji Yang, Xue-Ning Yang, Qing Zhou, Bin-Chao Wang, Wen-Zhao Zhong, Ling-Ling Gao, Wen-Bin Zhou, Ji Chen, Hai-Yan Tu, Ri-Qiang Liao, Dong-Kun Zhang, Shui-Lian Zhang, Dan-Xia Lu, Hong-Bo Zheng, Heng-Hui Zhang, Yi-Long Wu, Xu-Chao Zhang
Summary: This study retrospectively analyzed the data of metastatic PLELC patients treated with immune checkpoint inhibitors (ICI) and found that PD-L1 may serve as both a predictive biomarker for ICI treatment efficacy and a prognostic factor for survival in PLELC. In addition, PD-1/PD-L1 combined with LAG3 can be used as a predictive biomarker for ICI treatment effectiveness in PLELC.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Lan-Lan Pang, Jun Liao, Yi-Hua Huang, Jia-Di Gan, Wei-Tao Zhuang, Yi Lv, Wei-Ting Liang, Li Zhang, Wen-Feng Fang
Summary: Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare and distinctive subtype of nonsmall cell lung cancer (NSCLC). The potential of immunotherapy for advanced PLELC, characterized by high PD-L1 expression and scarcity of druggable driver mutations, remains unclear due to limited and inconclusive evidence on the clinical impact of immune-checkpoint inhibitors (ICIs).
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Immunology
Xiaoying Qian, Yong Wang, Fanrong Liu, Yong Yuan, Chen Fang, Xinwei Zhang, Shangkun Yuan, Renfang Chen, Biao Yu, Tong Wang, Yan Yin, Yong Li
Summary: This study retrospectively analyzed the efficacy of first-line immune checkpoint inhibitors (ICIs) in 21 patients with pulmonary sarcomatoid carcinoma (PSC). The results showed that first-line immunotherapy has promising therapeutic potential in the treatment of PSC, and no serious adverse events were noted. However, further research is needed to confirm these findings.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Ying Fan, Qianyun Shan, Jiali Gong, Jing Qin, Hongyang Lu
Summary: This study retrospectively reviewed data from 18 patients diagnosed with PPLELC at Zhejiang Cancer Hospital between 2009 and 2020, investigating the correlation between PD-L1 expression, clinicopathological characteristics, and treatment outcomes. The results showed that the prognosis of PPLELC is better than other NSCLC subtypes, and immunotherapy may be a promising approach to extend survival in advanced PPLELC patients.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Oncology
Hui-Zhao Hong, Jia-Kang Li, Jia-Tao Zhang, Li-Shan Peng, Yi-Long Wu, Wen-Zhao Zhong
Summary: This study aimed to investigate the effects of neoadjuvant immunotherapy on pulmonary lymphoepithelioma-like carcinomas (LELC). The results showed that neoadjuvant immunotherapy was effective in treating LELC and demonstrated comparable efficacy with respect to different histological subtypes.
Article
Gastroenterology & Hepatology
David J. Hermel, Emma Z. Du, Ray Lin, Catherine T. Frenette, Darren S. Sigal
Summary: LEL-HCC is a rare liver tumor with potential efficacy and safety of immune checkpoint blockade, although current evidence-based practices are lacking. A case report demonstrates successful treatment of LEL-HCC with an immune checkpoint inhibitor. More robust, large-scale analysis is needed for better evaluation of treatment strategies and outcomes for this rare tumor subtype.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Bojiang Chen, Yu Zhang, Sisi Dai, Ping Zhou, Wenxin Luo, Zhoufeng Wang, Xuping Chen, Peng Cheng, Guoya Zheng, Jing Ren, Xiaodong Yang, Weimin Li
Summary: This study explored the genomic features of pLELC and compared them with other types of lung cancer. It was found that pLELC patients had better survival rates and high PD-L1 or p53 expression was associated with extended disease-free survival. pLELC had 14 frequently mutated genes and two miR-BARTs were discovered to potentially be involved in tumorigenesis.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Article
Oncology
Anita Archwamety, Ruchira Ruangchira-urai, Charuwan Akewanlop, Krittiya Korphaisarn
Summary: Here, we present a case report of a late-stage PPLELC patient who showed a favorable response to ICIs treatment, which is the first of its kind in patients with PD-L1 expression in advanced PPLELC.
Article
Medicine, General & Internal
Liqin Zhang, Tairan Hao, Yuqing Wei, Mo Dong, Yuancheng Xiong
Summary: In this case report, a patient with stage IV PPLELC achieved a pathological complete response after neoadjuvant treatment, demonstrating significant effectiveness and safety.
Review
Oncology
Meng-Yu Chen, Yue-Can Zeng
Summary: The occurrence of pseudoprogression in lung cancer due to the application of immunotherapy has complicated clinical evaluation and management, highlighting the need for a better understanding of its mechanisms and strategies for differentiation.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Review
Oncology
Yuhei Miyasaka, Hiro Sato, Naoko Okano, Nobuteru Kubo, Hidemasa Kawamura, Tatsuya Ohno
Summary: Lung cancer is a leading cause of cancer-related deaths worldwide. Radiotherapy has achieved significant technical advances and is widely used in the management of lung cancer. The anti-tumor effect of radiotherapy is mainly caused by DNA damage in cancer cells. Additionally, radiotherapy induces anti-tumor immune responses, but also suppresses the immune system. Combining radiotherapy with immunotherapy, particularly immune checkpoint inhibitors, shows promise in overcoming immunosuppressive conditions in lung cancer patients. Particle therapy using protons and carbon ions in combination with immunotherapy is also a promising treatment strategy according to evidence outlined in this review.
Article
Oncology
Yi Xiao, Jinyuan He, Shaoning Luo, Min Dong, Wei Li, Gaijiao Liu, Hongjie Chen, Xiongwen Yang, Shaohong Huang
Summary: This study investigated the efficacy and safety of different treatment regimens for advanced pulmonary lymphoepithelioma-like carcinoma (pLELC). The results showed that chemoimmunotherapy had the highest 2-year progression-free survival (PFS) as a first-line treatment, suggesting that it may be the best treatment option for patients with advanced pLELC.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
David Reparaz, Belen Aparicio, Diana Llopiz, Sandra Hervas-Stubbs, Pablo Sarobe
Summary: Immune checkpoint inhibitors (ICI) show promising results but still have limitations in hepatocellular carcinoma (HCC) immunotherapy. Understanding immune elements in the tumor microenvironment may help personalize therapies and improve non-responder patients. Vaccination and boosting responses against tumor-specific antigens may complement ICI treatment in certain HCC cases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Jian-Ying Xu, Xiao-Li Wei, Yi-Qin Wang, Feng-Hua Wang
Summary: This review provides a comprehensive overview of the rationale, current status, advances, and challenges of immunotherapy in nasopharyngeal carcinoma (NPC). It focuses on the clinical application and advances of PD-1 inhibitor monotherapy and its combination with chemotherapy, as well as other immunotherapy approaches. The review also describes the clinical studies' status and challenges of immune checkpoint inhibitors (ICIs)-based immunomodulatory strategies in local advanced NPC, and highlights the biomarker application for personalized immunotherapy of NPC.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Yang Fu, Yue Zheng, Pei-Pei Wang, Yue-Yun Chen, Zhen-Yu Ding
Summary: The study demonstrated that in patients with LELC, immunotherapy showed higher objective response rates and disease control rates compared to chemotherapy. The depth of response was better in the ICI group, with significantly longer progression-free survival and higher 1-year PFS rate.
ONCOTARGETS AND THERAPY
(2021)